Loading…
DocGo Inc. operates as a mobile healthcare services company in the United States and the United Kingdom. It operates through Mobile Health Services and Transportation Services segments. The company offers transportation services comprising emergency response services; and non-emergency transport services, such as ambulance and wheelchair transportation services. It also provides mobile health services through its care delivery platform that are performed at home, offices, and other locations comprising mobile urgent care, exams, vaccinations, monitoring and care management, procedures, point-of-care tests, and screenings and coaching; event services, including on-site healthcare support at sporting events and concerts; virtual care management; and remote patient monitoring and chronic disease management services. The company serves municipalities, hospitals and health systems, states and communities, insurers, physician practices, health plans, and businesses and employees. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $322M | $-73M | $-182M | $27M | -126.7% | -47.7% | -1012.4% |
| 2024 | $617M | $45M | $20M | $65M | 6.2% | -1.2% | 191.5% |
| 2023 | $624M | $31M | $7M | $-74M | 2.3% | 41.7% | -80.2% |
| 2022 | $441M | $32M | $35M | $23M | 12.7% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 440.52 | 624.29 | 616.56 | 322.20 |
| Operating Revenue | - | 440.52 | 624.29 | 616.56 | 322.20 |
| Cost Of Revenue | - | 285.79 | 428.91 | 402.98 | 223.44 |
| Gross Profit | - | 154.72 | 195.38 | 213.57 | 98.76 |
| Operating Expense | - | 132.89 | 180.33 | 184.89 | 187.91 |
| Research And Development | - | 5.38 | 10.86 | 11.59 | 13.56 |
| Selling General And Administration | - | 116.94 | 153.04 | 157.41 | 158.69 |
| Total Expenses | - | 418.68 | 609.23 | 587.87 | 411.35 |
| Operating Income | - | 21.83 | 15.05 | 28.69 | -89.16 |
| Total Operating Income As Reported | - | 21.83 | 15.05 | 28.69 | -178.03 |
| EBITDA | - | 32.40 | 31.49 | 44.57 | -73.50 |
| Normalized EBITDA | - | 32.62 | 30.90 | 43.46 | 22.48 |
| EBIT | - | 21.83 | 15.05 | 28.69 | -89.16 |
| Interest Income | - | 0.76 | 1.68 | - | - |
| Interest Expense | 0.76 | - | - | 1.93 | - |
| Net Interest Income | - | 0.76 | 1.68 | -1.93 | -1.24 |
| Other Non Operating Income Expenses | - | 0.40 | -0.69 | 0.20 | -0.57 |
| Other Income Expense | - | 0.19 | -0.45 | 0.99 | -97.10 |
| Interest Income Non Operating | - | 0.76 | 1.68 | - | - |
| Interest Expense Non Operating | 0.76 | - | - | 1.93 | - |
| Net Non Operating Interest Income Expense | - | 0.76 | 1.68 | -1.93 | -1.24 |
| Pretax Income | - | 22.78 | 16.29 | 27.75 | -187.50 |
| Tax Provision | - | -7.96 | 6.24 | 14.39 | 8.87 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -0.05 | 0.22 | 0.23 | -20.15 |
| Net Income Continuous Operations | - | 30.74 | 10.05 | 13.36 | -196.37 |
| Net Income From Continuing And Discontinued Operation | - | 34.58 | 6.86 | 19.99 | -182.40 |
| Net Income From Continuing Operation Net Minority Interest | - | 34.58 | 6.86 | 19.99 | -182.40 |
| Net Income | - | 34.58 | 6.86 | 19.99 | -182.40 |
| Net Income Common Stockholders | - | 34.58 | 6.86 | 19.99 | -182.40 |
| Net Income Including Noncontrolling Interests | - | 30.74 | 10.05 | 13.36 | -196.37 |
| Normalized Income | - | 34.76 | 6.50 | 19.12 | -106.58 |
| Diluted NI Availto Com Stockholders | - | 34.58 | 6.86 | 19.99 | -182.40 |
| Basic Average Shares | 80.29 | 101.23 | 103.51 | 102.40 | - |
| Diluted Average Shares | 94.86 | 102.98 | 105.62 | 109.42 | - |
| Reconciled Depreciation | - | 10.57 | 16.43 | 15.88 | 15.66 |
| Reconciled Cost Of Revenue | - | 285.79 | 428.91 | 402.98 | 223.44 |
| Total Unusual Items | - | -0.22 | 0.58 | 1.11 | -95.97 |
| Total Unusual Items Excluding Goodwill | - | -0.22 | 0.58 | 1.11 | -95.97 |
| Minority Interests | - | 3.84 | -3.19 | 6.63 | 13.97 |
| Special Income Charges | - | -1.35 | 0.58 | 1.11 | -95.97 |
| Other Special Charges | -0.14 | - | 1 | - | - |
| Write Off | - | - | 0 | 0 | 5 |
| Impairment Of Capital Assets | - | 2.92 | 0 | 8.31 | 88.88 |
| Restructuring And Mergern Acquisition | - | -1.59 | -1.44 | -9.39 | 2.06 |
| Gain On Sale Of Security | 5.20 | 1.13 | - | - | - |
| Depreciation Amortization Depletion Income Statement | - | 10.57 | 16.43 | 15.88 | 15.66 |
| Depreciation And Amortization In Income Statement | - | 10.57 | 16.43 | 15.88 | 15.66 |
| General And Administrative Expense | - | 112.18 | 150.24 | 155.91 | 157.27 |
| Other Gand A | - | 112.18 | 150.24 | 155.91 | 157.27 |
| Gain On Sale Of Ppe | - | -0.02 | -0.85 | 0.02 | -0.04 |
| Total Other Finance Cost | - | -0.76 | -1.68 | 1.93 | 1.24 |
| Selling And Marketing Expense | - | 4.76 | 2.80 | 1.51 | 1.42 |
| Earnings From Equity Interest | - | 0.01 | -0.34 | -0.32 | -0.55 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| DocGo Inc.this co. | DCGO | $56M | -0.31 | 0.39 | -126.7% | -0.47 |
| Pulmonx Corporation | LUNG | $68M | - | 1.26 | -99.8% | - |
| LENSAR, Inc. | LNSR | $68M | -1.98 | -2.61 | 131.7% | -2.88 |
| aTyr Pharma, Inc. | ATYR | $50M | -0.68 | 0.75 | -109.8% | -0.68 |
| Myomo, Inc. | MYO | $50M | -3.20 | 4.37 | -136.6% |
| - |
| - |
| - |
| - |
| -4.36 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $46M | -2.09 | 5.86 | -280.5% | - |
| Accuray Incorporated | ARAY | $43M | -27.33 | 0.54 | -2.0% | 8.03 |
| Gossamer Bio, Inc. | GOSS | $42M | -0.24 | -0.34 | 138.8% | -1.31 |
| Tevogen Bio Holdings Inc. | TVGN | $41M | -1.57 | -2.42 | 154.2% | -1.89 |
| Peer Median | - | -1.98 | 0.64 | -50.9% | -1.60 | |